Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/53809
Title: | Patterns of care in the management of high-risk COPD in Australia (2015-2019): an observational study for the CONQUEST quality improvement program. | Authors: | Jenkins C.;Dickens A.P.;Evans A.;Le Cheng P.;Heraud F.;Hancock K.;Sharma A.;Cochrane B.;Roussos A.;Le Lievre C.;Blakey J.;Bosnic-Anticevich S.;Carter V.;Catanzariti A.;Ghisla C.;Hew M.;Ko B. ;Le T.;Leong P. ;McDonald V.M.;Lau C.M.;Perret J.L.;Pullen R.;Ranasinghe K.;Soriano J.B.;Stewart D.;van Melle M.;Wiseman R.;Price D. | Monash Health Department(s): | Cardiology (MonashHeart) Monash University - School of Clinical Sciences at Monash Health |
Institution: | (Jenkins) Head Respiratory Group, The George Institute and, UNSW, Sydney, Australia (Dickens, Evans, Le Cheng, Heraud, Roussos, Le Lievre, Carter, Le, Pullen, Price) Optimum Patient Care Australia, QLD, Australia (Hancock) Allergy and Lung Health Unit, Melbourne School of Population and Global Health, The University of Melbourne, VIC, Australia (Sharma) Platinum Medical Centre, Chermside, QLD, Australia (Cochrane) Campbelltown Hospital, Sydney, Australia (Blakey) Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia (Blakey) Curtin University Medical School, Perth, Australia (Bosnic-Anticevich) Woolcock Institute of Medical Research, 431 Glebe Point Road, Glebe, NSW, Australia (Bosnic-Anticevich) Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia (Bosnic-Anticevich, Catanzariti, Ghisla) Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, NSW, Australia (Ghisla) Novo Nordisk Medical Affairs, NSW, Australia (Hew) Allergy, Asthma & Clinical Immunology Service, Alfred Health, Melbourne, VIC, Australia (Hew) Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia (Ko) Victorian Heart Hospital, Monash Health and Monash Cardiovascular Research Centre, Monash University, Melbourne, VIC, Australia (Leong) Monash Heart, Monash Cardiovascular Research Centre and Monash University, Monash Health, Clayton, VIC, Australia (Leong) School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia (McDonald) School of Nursing and Midwifery, The University of Newcastle, Australia (Lau) Toukley Family Practice, 37-41 Canton Beach Road, Toukley, NSW, Australia (Perret) Allergy and Lung Health Unit, Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia (Ranasinghe) School of Medicine, Griffith University, Australia (Ranasinghe) Cannon Hill Family Doctors, Cannon Hill, Australia (Soriano) Facultat de Medicina, Universitat de les Illes Balears, Palma, Spain (Stewart) School of Medicine, University of Tasmania, Churchill Ave, Hobart, TAS, Australia (van Melle) Nictiz, The Hague, Netherlands (Wiseman) Suncoast Medical Centre, Coolum Beach, QLD, Australia (Soriano) Centro de Investigacion en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain (Cochrane) Western Sydney University, Sydney, Australia |
Issue Date: | 14-May-2025 | Copyright year: | 2025 | Publisher: | Elsevier Ltd | Place of publication: | United Kingdom | Publication information: | The Lancet Regional Health - Western Pacific. 58(no pagination), 2025. Article Number: 101555. Date of Publication: 01 May 2025. | Journal: | The Lancet Regional Health - Western Pacific | Abstract: | Background: We compared the management of patients with 'high-risk' COPD in Australia to national/international guidelines and quality standards, including the COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of COPD care (CONQUEST). Method(s): Eligible patients in the Optimum Patient Care Research Database Australia were categorized as newly diagnosed (<=12 months after diagnosis), already diagnosed, or patients with potential undiagnosed COPD, in each year from 2015 to 2019. 'High-risk' patients had >=2 COPD exacerbations/exacerbation-like events in the last 24 months. Descriptive statistics for 2019 are reported, along with annual trends. Finding(s): In 2019, 11.3% (2608/22,985) of eligible patients met high-risk criteria. Most newly diagnosed high-risk COPD patients (71.3%) had no recorded lung function testing within 12 months of diagnosis. 63.6% of new COPD diagnoses had no evidence of supporting spirometry or chest CT, with the remainder having recorded chest CT only. 44.3% of already diagnosed high-risk patients had no recorded inhaled maintenance therapy, although this was recorded for 11.2% of potential undiagnosed patients. Smoking cessation support and pulmonary rehabilitation were recorded for <40% and <=2% of diagnosed COPD patients respectively. Interpretation(s): There is substantial opportunity to improve diagnosis, assessment and treatment of patients with COPD in Australia by identifying, reviewing and managing high-risk patients in accordance with evidence-based guidelines and CONQUEST standards. Funding(s): This study was conducted by Optimum Patient Care Australia Pty Ltd (OPCA) and was partially funded by OPCA and AstraZeneca Pty Ltd. No funding was received by the Observational & Pragmatic Research Institute Pte Ltd (OPRI) for its contribution.Copyright © 2025 The Author(s) | DOI: | http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1016/j.lanwpc.2025.101555 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/53809 | Type: | Article | Subjects: | anemia asthma bronchiectasis cardiovascular disease chronic kidney failure chronic obstructive lung disease cystic fibrosis depression heart failure hypertension influenza vaccination lung cancer |
Type of Clinical Study or Trial: | Observational study (cohort, case-control, cross sectional, or survey) |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.